Skip to main content
. 2015 Jun 29;112(28):8650–8655. doi: 10.1073/pnas.1500886112

Fig. 2.

Fig. 2.

miR-148a induces TRAIL sensitivity in NSCLC by targeting MMP15. (A) Proliferation assay in A549 cells transfected with control miR or miR-148a for 48 h followed by 24-h TRAIL treatment (200 ng/mL). Cells overexpressing miR-148a were more sensitive to TRAIL-induced apoptosis. (B) Caspase-8 and caspase-3/7 activity assay in A549 cells transfected with control miR or miR-148a after TRAIL treatment (100 ng/mL) over a 4-h time period. (C) Western blot showing PARP-1 activation after 6 h TRAIL treatment (100 and 200 ng/mL) in A549 cells transfected with control miR or miR-148a. (D) Annexin-V staining showing increased sensitivity of Calu-1 cells to TRAIL-induced apoptosis 48 h after being transfected with miR-148a. Cells were treated with 1 μg/mL TRAIL. M2 is percentage of apoptotic cells. (E) Proliferation assay in H460 cells transfected with control or MMP15 cDNA after TRAIL treatment (25 and 50 ng/mL). (F) Caspase-3/7 activity assay in H460 cells after MMP15 overexpression and TRAIL treatment. Cells overexpressing MMP15 showed resistance to TRAIL-induced apoptosis. (G) Western blot showing caspase-8 activation after 3-h TRAIL treatment (25 and 50 ng/mL) in H460 cells transfected with control or MMP15 cDNA. Data are presented as ± SD; *P < 0.05 and **P < 0.01 by Student’s t test.